Enovis vs Envista
ENOV and NVST side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENOV and NVST compare
Envista is the larger company, worth 2.4 times as much as Enovis ($3.8B against $1.6B).
Envista grew revenue faster over the last twelve months (11.9% versus 4.9% for Enovis).
Envista keeps more of each dollar of sales as profit, with a net margin of 3.3% compared with −48.0% at Enovis.
Envista scores higher on the StockData Score (14 against 8 for Enovis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENOV | NVST |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $3.8B |
| Share price | $27.22 | $23.70 |
| Change, 1 year | −9.2% | 22.2% |
| Change, 5 years | −81.3% | −40.9% |
| Beta (5Y) | 0.08 | 0.54 |
| Employees | 7,802 | 12K |
| StockData Score | ||
| Total score | 8 | 14 (better) |
| Valuation score | 4 (better) | 3 |
| Growth score | 2 | 4 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 40.9× |
| P/S | 0.7× (better) | 1.3× |
| P/B | 1.1× (better) | 1.2× |
| EV/EBITDA | 9.2× (better) | 10.6× |
| P/FCF | 24.7× | 15.3× (better) |
| FCF yield | 4.1% | 6.5% (better) |
| Fair value | $81.07 | $28.73 |
| Margin of safety | 66.4% (better) | 17.5% |
| Growth | ||
| Revenue growth (TTM) | 4.9% | 11.9% (better) |
| Revenue growth, 5Y average | 14.9% (better) | 7.1% |
| Net income growth (TTM) | – | 76.6% |
| EPS growth (TTM) | – | 81.3% |
| EPS growth, 5Y average | – | 7.0% |
| Profitability | ||
| Gross margin | 61.1% (better) | 55.2% |
| Operating margin | −45.1% | 9.6% (better) |
| Net margin | −48.0% | 3.3% (better) |
| FCF margin | 2.8% | 8.7% (better) |
| Return on equity | −54.3% | 3.1% (better) |
| Return on invested capital | −24.5% | 4.0% (better) |
| Financial health | ||
| Debt / equity | 0.87 | 0.47 (better) |
| Net debt / EBITDA | 4.12 | 0.80 (better) |
| Interest coverage | −30.9× | – |
| Current ratio | 1.98 | 2.43 (better) |
| Altman Z-score | −0.24 | 1.74 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 4.4% |
| Shareholder yield | 0.00% | 4.4% (better) |
| Ownership | ||
| Held by institutions | 122% | 118% |
| Held by insiders | 2.7% | 0.85% |
| Insider net buying, 12 months | $842K (better) | −$510K |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 18.8% | 6.1% |
Go deeper
- ENOV stock overview
- ENOV income statement
- ENOV valuation and score
- NVST stock overview
- NVST income statement
- NVST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.